Impact of hypofractionated schemes in radiotherapy for locally advanced head and neck cancer patients

被引:12
|
作者
Franzese, Ciro [1 ]
Fogliata, Antonella [1 ]
Franceschini, Davide [1 ]
Navarria, Pierina [1 ]
Cozzi, Luca [1 ,3 ]
Tomatis, Stefano [1 ]
De Virgilio, Armando [2 ]
Spriano, Giuseppe [2 ,3 ]
Scorsetti, Marta [1 ,3 ]
机构
[1] Humanitas Res Hosp & Canc Ctr, Dept Radiat Oncol, Via Manzoni 56, I-20089 Milan, Italy
[2] Humanitas Res Hosp & Canc Ctr, Otolaryngol Head & Neck Surg Dept, Milan, Italy
[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy
来源
LARYNGOSCOPE | 2020年 / 130卷 / 04期
关键词
Head and neck cancer; radiotherapy; hypofractionation; oropharynx; margin; INTENSITY-MODULATED RADIOTHERAPY; SQUAMOUS-CELL CARCINOMA; POSTOPERATIVE RADIOTHERAPY; OROPHARYNGEAL CARCINOMA; CHEMORADIATION; DAHANCA; VOLUME; TUMORS; TRIAL;
D O I
10.1002/lary.28048
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective To analyze two cohorts of locally advanced head and neck cancer (LAHNC) patients treated with two schedules of hypofractionated radiotherapy and 5 versus 3 mm clinical target volume-planning target volume (CTV-PTV) margins. Methods 145 patients were included. The patient cohort was divided into two groups. Group A included 97 patients treated with 69.96/54.45 grays (Gy) to the high-risk and low-risk volumes, respectively, in 33 fractions, with 5 mm margins. Group B included 48 patients treated with 66/54 Gy in 30 fractions using 3 mm margins. Toxicity was recorded according to the Common Toxicity Criteria version 3. Patient outcomes for locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) were determined. Results Median follow-up was 26 months. In terms of toxicity, acute dysphagia worsened significantly (P = 0.003) in group B, whereas acute salivary toxicity tended to significance (P = 0.071). No significant late toxicity differences were recorded. Rates of LRC at 1 and 2 years were 90.1% +/- 2.6% and 84.2% +/- 3.4%, respectively, with superiority for group A (P = 0.045). The statistical significance remained for the low-dose level (P = 0.007) but not for high dose (P = 0.110). Rates of DFS at 1 and 2 years were 84.9% +/- 3.1% and 76.5% +/- 3.9%, respectively, whereas rates of OS were 95.9% +/- 1.8% and 91.6% +/- 2.7%, respectively. No differences were observed between the two groups in terms of DFS (P = 0.270) and OS (P = 0.152). Conclusion The use of reduced CTV to PTV margins and dose reduction with hypofractionation schedule can improve the pattern of toxicity in LAHNC patients. This approach resulted in an increased rate of locoregional progression, particularly in low-risk regions. Level of Evidence 4 Laryngoscope, 130:E163-E170, 2020
引用
收藏
页码:E163 / E170
页数:8
相关论文
共 50 条
  • [1] Hypofractionated Radiotherapy plus Cetuximab in Locally Advanced Head and Neck Cancer
    Teoh, D. C.
    Rodger, S.
    Say, J.
    Hartley, A.
    [J]. CLINICAL ONCOLOGY, 2008, 20 (09) : 717 - 717
  • [2] Moderately hypofractionated Radiotherapy without Chemotherapy in elderly and frail Patients with locally advanced Head and Neck Cancer
    Fryen, A.
    Brandes, I.
    Wichmann, J.
    Christiansen, H.
    Tavassol, F.
    Durisin, M.
    Merten, R.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S113 - S114
  • [3] Hypofractionated, palliative radiotherapy for advanced head and neck cancer
    Agarwal, Jai Prakash
    Nemade, Bhushan
    Murthy, Vedang
    Ghosh-Laskar, Sarbani
    Budrukkar, Ashwini
    Gupta, Tejpal
    D'Cruz, Anit
    Pai, Prathamesh
    Chaturvedi, Pankaj
    Dinshaw, Ketayun
    [J]. RADIOTHERAPY AND ONCOLOGY, 2008, 89 (01) : 51 - 56
  • [4] Hypofractionated Palliative Radiotherapy in Locally Advanced Inoperable Head and Neck Cancer: CMC Vellore Experience
    Das, Saikat
    Thomas, Solly
    Pal, Suparna Kanti
    Isiah, Rajesh
    John, Subhashini
    [J]. INDIAN JOURNAL OF PALLIATIVE CARE, 2013, 19 (02) : 93 - 98
  • [5] Induction capecitabine and cisplatin followed by hypofractionated radiotherapy in locally advanced head and neck cancer.
    Hashmi, Quratul Ain
    Mateen, Abdul
    Khan, Muhammad Saqib
    Adil, Allah Rakha
    Duraishi, Arif Moin
    Abdullah, Famya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Nivolumab and ipilimumab in combination with radiotherapy in patients with locally advanced head and neck cancer
    Johnson, J. M.
    Bar Ad, V.
    Lorber, E.
    Luginbuhl, A.
    Curry, J. M.
    Cognetti, D.
    Keith, S.
    Axelrod, R.
    Zinner, R.
    Rodeck, U.
    Harshyne, L. A.
    Argiris, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [7] Radiotherapy combined with Cetuximab for locally advanced head and neck cancer
    Acevedo-Henao, C-M
    Valette, G.
    Marianowski, R.
    Pradier, O.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 : 96 - 96
  • [8] Locally advanced head and neck cancer: chemoradiotherapy or acceleration of radiotherapy?
    Mazeron, Jean-Jacques
    [J]. BULLETIN DU CANCER, 2012, 99 (10) : 901 - 902
  • [9] Hypothyroidism after Radiotherapy of Locally Advanced Head and Neck Cancer
    Lee, Jeong Eun
    Kim, Jae-Chul
    Yea, Ji Woon
    Park, In Kyu
    [J]. RADIATION ONCOLOGY JOURNAL, 2010, 28 (02): : 64 - 70
  • [10] POSTOPERATIVE RADIOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK-CANCER
    FRANCHIN, G
    DEPAOLI, A
    GOBITTI, C
    BOZ, G
    MINATEL, E
    RONCADIN, M
    ARCICASA, M
    BORTOLUS, R
    INNOCENTE, R
    TROVO, GM
    GRIGOLETTO, E
    [J]. TUMORI, 1989, 75 (01) : 47 - 52